Skip to main content
. 2022 Jan 31;14(3):743. doi: 10.3390/cancers14030743

Figure 1.

Figure 1

Schematic representation of utilizing cell-free DNA as a biomarker to evaluate minimal residual disease pre-and post-transplant (cancer recurrence), and liver transplant rejection using the Signatera and ProsperaTests, respectively. Figures created with Biorender.com.